TY - JOUR
T1 - JCL Roundtable. Making prevention a priority
AU - Agarwala, Anandita
AU - Goldberg, Anne C.
AU - Ballantyne, Christie M.
AU - Guyton, John R.
N1 - Funding Information:
Dr. Agarwala reports none. Dr. Goldberg reports grant/research support (all to institution) from Amarin, Amgen, IONIS/Akcea, Novartis, Regeneron, Pfizer, Sanofi, The FH Foundation; consulting for Akcea, Esperion, Novartis, Regeneron; honoraria from Merck, the National Lipid Association. Dr. Ballantyne reports grant/research support (all paid to institution, not individual) from Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, NIH, AHA, ADA; consulting for Abbott Diagnostics, Akcea, Amarin, Amgen, Astra Zeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo. Dr. Guyton has received research support from Regeneron.
Publisher Copyright:
© 2021
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Clinical lipidology belongs par excellence to the preventive mode of medical practice. This Roundtable brings two long-time advocates of cardiometabolic prevention and a newly minted preventive cardiologist into a discussion that expands their recent JCL editorial on this topic. Atherosclerosis is a single disease process that leads to approximately 25% of deaths in economically advanced nations and a growing fraction of mortality and morbidity in nations with developing and emerging economies. Our discussants suggest that at least 75% of atherosclerotic cardiovascular disease can be prevented. Diet and lifestyle including physical activity are the cornerstones for this effort. Public and private choices about diet-lifestyle are influenced by economics, education (especially in childhood), inequities, technology, misinformation, and trust. Lipid clinics perform well with pharmacologic treatment of lipid disorders and increasingly give attention to hypertension, obesity, and diabetes as needed. Cardiometabolic prevention in the clinic works best through provider teams. Business considerations and exemplary programs are highlighted.
AB - Clinical lipidology belongs par excellence to the preventive mode of medical practice. This Roundtable brings two long-time advocates of cardiometabolic prevention and a newly minted preventive cardiologist into a discussion that expands their recent JCL editorial on this topic. Atherosclerosis is a single disease process that leads to approximately 25% of deaths in economically advanced nations and a growing fraction of mortality and morbidity in nations with developing and emerging economies. Our discussants suggest that at least 75% of atherosclerotic cardiovascular disease can be prevented. Diet and lifestyle including physical activity are the cornerstones for this effort. Public and private choices about diet-lifestyle are influenced by economics, education (especially in childhood), inequities, technology, misinformation, and trust. Lipid clinics perform well with pharmacologic treatment of lipid disorders and increasingly give attention to hypertension, obesity, and diabetes as needed. Cardiometabolic prevention in the clinic works best through provider teams. Business considerations and exemplary programs are highlighted.
UR - http://www.scopus.com/inward/record.url?scp=85119450387&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2021.08.004
DO - 10.1016/j.jacl.2021.08.004
M3 - Article
C2 - 34815066
AN - SCOPUS:85119450387
SN - 1933-2874
VL - 15
SP - 530
EP - 537
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 4
ER -